NICE backs Xarelto for pulmonary embolism

The U.K.'s NICE issued a Xarelto rivaroxaban from Bayer AG (Xetra:BAYN) to treat pulmonary embolism (PE) and prevent recurrent deep vein thrombosis (DVT) and PE following acute PE in adults. NICE said the most plausible incremental cost-effectiveness ratio (ICER) for lifelong treatment with the oral Factor Xa inhibitor vs. lifelong treatment with a vitamin K antagonist was between L17,900-L22,900 ($27,448-$35,115) per quality-adjusted life year (QALY). Final guidance is expected next month. ...